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Rapid degradation of mutant SLC25A46 by  
the ubiquitin-proteasome system results in 
MFN1/2-mediated hyperfusion of mitochondria
ABSTRACT SCL25A46 is a mitochondrial carrier protein that surprisingly localizes to the 
outer membrane and is distantly related to Ugo1. Here we show that a subset of SLC25A46 
interacts with mitochondrial dynamics components and the MICOS complex. Decreased 
expression of SLC25A46 results in increased stability and oligomerization of MFN1 and MFN2 
on mitochondria, promoting mitochondrial hyperfusion. A mutation at L341P causes rapid 
degradation of SLC25A46, which manifests as a rare disease, pontocerebellar hypoplasia. 
The E3 ubiquitin ligases MULAN and MARCH5 coordinate ubiquitylation of SLC25A46 L341P, 
leading to degradation by organized activities of P97 and the proteasome. Whereas outer 
mitochondrial membrane–associated degradation is typically associated with apoptosis or a 
specialized type of autophagy termed mitophagy, SLC25A46 degradation operates indepen-
dently of activation of outer membrane stress pathways. Thus SLC25A46 is a new component 
in mitochondrial dynamics that serves as a regulator for MFN1/2 oligomerization. Moreover, 
SLC25A46 is selectively degraded from the outer membrane independently of mitophagy 
and apoptosis, providing a framework for mechanistic studies in the proteolysis of outer 
membrane proteins.
INTRODUCTION
The mitochondrial network is maintained by a combination of fusion 
and fission events. Defects in this fine balance can cause numerous 
diseases, including cancer, cardiac disease, and particularly neurode-
generation (Archer, 2013). Fission and fusion are regulated by a small 
subset of dynamin-related guanosine triphosphatases (GTPases) 
located in the cytosol or inner (IM) and outer (OM) mitochondrial 
membranes. On activation, the dynamin-related protein 1 (DRP1) 
oligomerizes on mitochondria, forming a ring-like structure that con-
stricts and finally divides the mitochondria. Fusion is mediated by the 
GTPases optic atrophy 1 (OPA1) on the IM and mitofusins 1 and 2 
(MFN1 and MFN2) on the OM. OPA1 consists of approximately eight 
mRNA OPA1 isoforms in humans (Delettre et al., 2001). IM-bound 
long (L)-OPA1 forms can be processed by proteolytic cleavage to 
generate short (S)-OPA1 (Ishihara et al., 2006). OM fusion is regu-
lated by MFN1 and MFN2 (Santel and Fuller, 2001; Chen et al., 
2003). MFN1 and MFN2 form homo- and hetero-oligomers on the 
OM and are required for an elongated mitochondrial network 
(Detmer and Chan, 2007). Deletion of MFN1 or MFN2 is embryonic 
lethal. Moreover, MFN1 and MFN2 differ in their expression in vari-
ous tissues (Bertholet et al., 2016), which may result in independent 
functions. Whereas mutations in MFN2 are associated with ∼20% of 
Charcot–Marie–Tooth (CMT) type 2 cases—an inherited peripheral 
neuropathy (Züchner et al., 2004; Verhoeven et al., 2006)—no dis-
ease has been associated with mutations in MFN1.
Misfolded proteins within mitochondria are removed by the co-
ordinated action of chaperones and proteases (Quiros et al., 2015). 
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Janer et al., 2016; Wan et al., 2016). After lysis in 1% digitonin, 
SLC25A46 mostly interacted with proteins involved in fission and 
fusion such as MFN1/2 or OPA1 and with components of the MI-
COS complex (Supplemental Table S1). A subset of these potential 
interaction partners was confirmed by a variety of approaches. First, 
we solubilized mitochondria that contained SLC25A46 with an N-
terminal HA tag in 1% digitonin and used glycerol gradients to ex-
amine the distribution of mitochondrial proteins (Figure 1A). 
SLC25A46 WT mostly migrated near the center of the gradient in 
fractions 7–13. Migration of OM proteins MFN1 and MTCH2 was 
also enriched in similar fractions as the SLC25A46 WT protein. In-
stead, MIC60, MIC27, and MIC19 of the MICOS complex and 
TOMM40 migrated in heavier fractions (Bohnert et al., 2015; Fried-
man et al., 2015). Additional controls included PNPase and YME1L 
of the intermembrane space, TIMM23 in the IM, and matrix-local-
ized PreP and LRP130, which all showed a different distribution pat-
tern than SLC25A46. To assess SLC25A46 and MFN1 binding, anal-
ysis of coimmunoprecipitation (coIP) fractions 9, 11, and 13 revealed 
that a subset of MFN1 and MFN2 indeed interacted with SLC25A46 
(Figure 1B). The interactions between SLC25A46 and MFN1/MFN2 
were specific because OM protein MID51 did not copurify with 
SLC25A46 WT or L341P in similar coIP experiments (Figure 2A). We 
also used the glycerol gradient system to probe the assembly of 
SLC25A46 L341P from a similar cell line—a stable HEK293T cell line 
expressing 2xHA-SLC25A46 L341P. In contrast, SLC25A46 L341P 
was less abundant and sedimented in fractions 17–23, near the bot-
tom of the gradient (Figure 1A and Supplemental Figure S1B). Com-
plexes of TOMM40, MFN1 and MIC60 were not altered in mito-
chondria with SLC25A46 L341P (Supplemental Figure S1B).
Using blue-native (BN) gels, we also investigated the migration 
of SLC25A46 WT and L341P, as well as that of partner proteins. The 
majority of SCL25A46 WT was at a molecular mass of 70–200 kDa, 
but larger complexes were also identified (Figure 1C). In contrast, 
the majority of SCL25A46 L341P migrated at a larger size, >600 
kDa, but SLC25A46 L341P could be detected throughout the gel. In 
mitochondria from LAN5 neuronal cells (Figure 1D), endogenous 
SLC25A46 migrated in similar-sized complexes as in HEK293T cells 
expressing HA-SCL25A46. MFN1, MFN2, and MTCH2 also comi-
grated with SLC25A46 (Figure 1, C–E; MFN1/2–SLC25A46 complex 
[▪] and MTCH2–SLC25A46 complex [▴]), and a small amount of 
SLC25A46 was detected in the larger complex that comigrated with 
MIC19 and MIC60 (Figure 1, D and E; MICOS–SLC25A46 complex 
is marked with an asterisk). TOMM40 did not comigrate with 
SLC25A46 (Figure 1C). Complexes of TOMM40, MFN1, and MIC60 
were not altered in mitochondria with SLC25A46 L341P (Supple-
mental Figure S1B). Thus the BN-gel assay supports that mutation 
L341P in SLC25A46 alters its complex formation. Moreover, the WT 
SLC25A46 comigrated with dynamics proteins MFN1 and MFN2 in 
addition to MTCH2, and a small amount of SLC25A46 comigrated 
with the MICOS complex. In sum, SLC25A46 associates with several 
proteins and may function as a scaffold for assembly of proteins 
involved in mitochondrial ultrastructure.
Because the interactions between SLC25A46 and protein part-
ners may be transient or weak, we performed intracellular cross-
linking followed by cell solubilization and coIP assays (Figure 2A). 
This seemed to trap interactions because SLC25A46 coprecipi-
tated with OPA1 (short and long forms; DeVay et al., 2009), MFN1, 
MFN2, and MICOS components MIC60 and MIC19. This agrees 
with our previous study (Wan et al., 2016) and recent publications 
that SLC25A46 is a component similar to yeast Ugo1, which main-
tains mitochondrial morphology (Abrams et al., 2015; Janer et al., 
2016). In addition, TOMM40 interacted with SLC25A46, which 
The ubiquitin-proteasome system (UPS) removes proteins from the 
OM (Campello et al., 2014). Typical substrates are proteins involved 
in mitochondrial dynamics and apoptosis (Karbowski and Youle, 
2011). Several E3 ubiquitin ligases have been associated with mito-
chondria. The RING E3 ligase MARCH5/MITOL is a multispanning 
OM protein that ubiquitylates primary substrates DRP1 and FIS1 
(Nakamura et al., 2006; Yonashiro et al., 2006; Karbowski et al., 
2007). MULAN/MAPL/MUL1 is another RING E3 ligase anchored to 
the mitochondrial OM that ubiquitylates MFN1/2 and sumoylates 
DRP1 (Braschi et al., 2009; Lokireddy et al., 2012). A few cytosolic E3 
ligases, such as PARKIN and HUWE1/MULE/HECTH9, are recruited 
to mitochondria and ubiquitylate MFN2 and other OM substrates to 
activate mitophagy and apoptosis, respectively (Narendra et al., 
2008; Leboucher et al., 2012). The E3 ligases likely have overlap-
ping specificities to maintain OM homeostasis and regulate mitoph-
agy. For example, MULAN acts in parallel to the PINK1-PARKIN 
pathway, and different E3 ligases seem to have differing importance 
in different tissues and conditions (Livnat-Levanon and Glickman, 
2011; Yun et al., 2014). After ubiquitylation, OM proteins are ex-
tracted from the membrane by the AAA ATPase P97/VCP and sub-
sequently degraded by the proteasome in the cytosol (Heo et al., 
2010; Tanaka et al., 2010).
In a recent study (Wan et al., 2016), we found that SLC25A46 is 
an OM protein that, when deleted or mutated (L341P), leads to hy-
perfused mitochondria and finally to lethal pontocerebellar hypo-
plasia (PCH). Similar results focused on different mutations in 
SLC25A46 have been recently published (Abrams et al., 2015; Janer 
et al., 2016). Mutations in SLC25A46 have been associated with 
dominant optic atrophy (DOA) and CMT type 2, and the mitochon-
dria have increased mitochondrial connectivity (Abrams et al., 2015). 
In addition, a family with a missense mutation in SLC25A46 exhib-
ited Leigh syndrome, and the physiological phenotype was charac-
terized by defects in mitochondrial lipid homeostasis, cristae main-
tenance, and bioenergetics (Janer et al., 2016).
In this study with cell models, the underlying cause of PCH is 
likely loss of function from selective degradation of SLC25A46 that 
harbors a mutation in the putative fifth membrane-spanning domain. 
Here we study the underlying mechanism resulting in hyperfusion 
of mitochondria and the specific pathway for selective degradation 
of mutant SLC25A46 L341P. We show that MFN1 and MFN2 accu-
mulate on mitochondria in an oligomeric state in cells lacking 
SLC25A46 or expressing SLC25A46 L341P, which results in en-
hanced fusion. Further, our data indicate that MARCH5 and MULAN 
coordinate the degradation of SLC25A46 and seem to have redun-
dant functions.
RESULTS
SLC25A46 associates with several OM proteins, particularly 
components in mitochondrial dynamics
In a previous study, we found that rare cases of PCH were likely 
caused by a deletion in exon 1 (causing gene disruption) or a point 
mutation in exon 8 in mitochondrial OM protein SLC25A46 (leucine 
at position 341 is replaced with proline, designated L341P (Wan 
et al., 2016); SLC25A46 L341P was not stable, and the mitochondria 
displayed hyperfused mitochondria and other aberrant morpholo-
gies (Wan et al., 2016). To investigate the potential function of 
SLC25A46, we performed immunoprecipitations and mass spec-
trometry analysis on mitochondria isolated from a stable HEK293T 
cell line expressing wild-type (WT) SLC25A46 tagged with a 2× 
hemagglutinin (HA) epitope at the N-terminus. A tag placed at ei-
ther the N- or the C-terminus did not interfere with insertion into the 
mitochondrial OM (Supplemental Figure S1A; Abrams et al., 2015; 
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require a method such as cross-linking for 
stabilization.
The clustered regularly interspaced 
short palindromic repeats (CRISPR)/Cas9 
system was used to knock out SLC25A46 
from the HCT116 cell line. SLC25A46 was 
successfully deleted, and three representa-
tive monoclonal cell lines (designated 1.7, 
4.1, 4.3 SLC25A46 −/−) were chosen for ad-
ditional characterization. The analysis of 
steady-state levels of partner proteins 
identified in Figure 2A was tested by 
immuno blotting (Figure 2B). The abun-
dance of most of these proteins was not 
altered, indicating that SLC25A46 is not a 
bona fide partner protein with the MICOS 
complex. However, we observed a slight 
increase in the levels of mitochondrial dy-
namics proteins MFN1 and MFN2 (Figure 
2B). We also observed increased steady-
state levels of MFN1 and MFN2 in mito-
chondria when SLC25A46 was knocked 
out in the cell line HEK293 T-REx Flp-In 
(Figure 2, C and D). Specifically, the abun-
dance of MFN1/2 increased ∼1.6- and 
2-fold, respectively (Figure 2D). To analyze 
whether these elevated levels were caused 
by enhanced protein import, we imported 
radiolabeled MFN1-13myc and MFN2-
20myc (Chen et al., 2003) into isolated mi-
tochondria from WT and SLC25A46−/− 
HEK293 T-REx Flp-In cells and analyzed 
the import by SDS–PAGE and BN-PAGE 
(Supplemental Figure S2, A and B). The 
presence of the additional myc tags on the 
C-terminus of MFN1 and MFN2 does not 
interfere with function or assembly (Chen 
et al., 2003) but results in increased mole-
cular weight (Supplemental Figure S2, A 
and B). Imported MFN1 and MFN2 were 
recovered in the pellet fraction after alkali 
extraction. For both proteins, we did not 
observe any changes in protein import. We 
also included control import reactions that 
lacked mitochondria to confirm that MFN1 
and MFN2 did not nonspecifically fraction 
in the pellet after alkali extraction; MFN1 
and MFN2 were not recovered in the pellet 
fraction in the absence of mitochondria 
(Supplemental Figure S2A). We also did 
not note any differences in MFN1 and 
MFN2 expression in HEK293 T-REx Flp-In 
SLC25A46 knockout cells using quantitative PCR (qPCR; Figure 
2E). Thus the knockout of SLC25A46 stabilizes MFN1 and MFN2 
on mitochondria because of decreased degradation of MFN1 and 
MFN2.
SLC25A46 does not function in mitochondrial phospholipid 
biogenesis and trafficking pathways
Because the MICOS complex has been implicated in lipid biogen-
esis and trafficking and SLC25A46 yeast homologue Ugo1 was 
believed to regulate the local lipid composition of the OM 
may reflect a role for TOMM40 in SLC25A46 assembly. SCL25A46 
L341P also bound to similar proteins but showed an increased 
binding with TOMM40, MTCH2, and MULAN, an E3 ubiquitin li-
gase that functions in turnover of OM proteins (Braschi et al., 2009; 
Ambivero et al., 2014; Yun et al., 2014). However, SLC25A46 did 
not display strong binding to MIC27. To confirm specificity of 
SLC25A46 interactions with OM proteins, we found that MID51 
did not copurify with SLC25A46 (Figure 2A). This immunoprecipi-
tation experiment under cross-linking conditions supports that 
SLC25A46 interactions with partner proteins may be transient and 
FIGURE 1: SLC25A46 comigrates with mitochondrial dynamics and MICOS proteins. 
(A) Glycerol gradient density centrifugation of mitochondrial extracts generated from a stable 
cell line expressing 2xHA-SLC25A46 WT. Mitochondria were solubilized in 1% digitonin, and 
lysates were loaded on a linear 10–50% glycerol gradient and centrifuged overnight. Fractions 
1–23 were analyzed with the indicated antibodies. A similar sample was included, and 
the HA antibody was used to determine SLC25A46 L341P assembly. SM, starting material. 
(B) Immunoprecipitation (IP) with the HA antibody of 2xHA-SLC25A46 WT from the indicated 
fractions (1, 9, 11,13) of the glycerol gradient density centrifugation in A. Input samples 
correspond to 10% of each fraction. Antibodies against HA, MFN1, and MFN2 were used. 
(C) Mitochondria isolated form HEK293T cells stably expressing 2xHA-SLC25A46 WT or L341P 
were solubilized with digitonin, and mitochondrial extracts were resolved by two-dimensional 
BN-PAGE. Antibodies against MFN1, TOMM40, PreP, and HA were used for immunoblotting. 
For MFN1, TOMM40, and PreP, the analysis from WT mitochondria is shown, and the complexes 
migrated identically in mitochondria from the SLC25A46 L341P cell line. (▪) The MFN1-
SLC25A46 complex. (D, E) Mitochondria were isolated from LAN5 cells and then lysed in 1% 
digitonin. Mitochondrial extracts were resolved by one- (D) or two- (E) dimensional BN-PAGE; 
antibodies for endogenous SLC25A46, MIC19, MIC60, MFN2, and MTCH2 were included. In D, 
shorter and longer exposures for SLC25A46 are shown to highlight the larger complex that 
comigrates with the MICOS complex. (▪) The MFN1-SLC25A46 complex; (▴) the MICOS-
SLC25A46 complex; (*) the MTCH2-SLC25A46 complex.
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(Hoppins et al., 2009; Anton et al., 2011), 
we assessed whether mitochondrial lipid 
levels were altered in SLC25A46−/− cells. To-
tal phospholipid content in mitochondria 
was analyzed, and no differences were de-
tected (Supplemental Figure S3A). The lipid 
profile was assessed using thin-layer chro-
matography (Supplemental Figure S3B), 
and the individual phospholipids were 
quantitated (Figure 2F). The profile of the 
individual lipids was not different in the 
SLC25A46−/− cell lines than in WT HCT116 
cells. Thus SLC25A46 does not play a direct 
role in lipid biogenesis or lipid trafficking.
The abundance of MFN1 and MFN2 is 
increased in cells lacking SLC25A46
Because we observed higher steady-state 
levels of MFN1 and MFN2 in cells lacking 
SLC25A46, we investigated the assembly of 
these proteins. Because SLC25A46 is highly 
expressed in neuronal tissue and mutant 
SLC25A46 impairs neuronal function 
(Haitina et al., 2006; Abrams et al., 2015; 
Wan et al., 2016), we used short hairpin 
RNAs (shRNAs) to knock down SLC25A46 
in LAN5 cells (Figure 3, A and B). As ob-
served in HCT116 and HEK293 T-REx Flp-
In SLC25A46−/− cells, the steady-state levels 
of MFN1 and MFN2 were slightly elevated 
after SLC25A46 knockdown (Figure 3A). 
This led to an elevated abundance of 
MFN1 and MFN2 complexes in cells lacking 
SCL25A46 when isolated mitochondria 
were solubilized in digitonin and separated 
by BN-PAGE (Figure 3B). Again, we did not 
observe any marked changes in the expres-
sion of transcripts for MFN1 and MFN2 
(Figure 3C). We obtained similar results in 
HCT116 SLC25A46−/− cells (Supplemental 
Figure S4).
To determine whether the enhanced 
oligomerization states of MFN1 and MFN2 
lead to hyperfused mitochondria, we 
knocked down SLC25A46 in LAN5 cells by 
RNA interference (RNAi) and visualized mi-
tochondria by immunofluorescence stain-
ing using an antibody against the matrix 
protein Mortalin and the OM protein 
TOMM20. As expected, mitochondria ap-
peared elongated and hyperfused in cells 
with SLC25A46 knock down, as reported 
previously (Figure 3D; Abrams et al., 2015; 
Janer et al., 2016; Wan et al., 2016). To 
confirm that the mitochondrial network 
was indeed hyperfused in SLC25A46-
knockdown cells, we quantitated the mito-
chondrial network (Figure 3E). In cells that 
lacked SLC25A46, the network consisted 
of ∼65% hyperfused and ∼30% normal mi-
tochondria. In contrast, the control cells 
had a network with ∼70% normal and 
FIGURE 2: SLC25A46 interacts with proteins important for mitochondrial biogenesis and 
morphology. (A) IP with the HA antibody from whole-cell extracts of HEK293T or stable HEK293T 
cells expressing 2xHA-SLC25A46 WT or 2xHA-SLC25 L341P. Cells were cross-linked with 
dithiobis(succinimidyl propionate) before lysis. Samples were analyzed with the indicated 
antibodies. Input samples represent 2% of the material used for the IP. Short (S) and long (L) forms 
of OPA1 are marked. (B) Steady-state level of SLC25A46 interaction partners in HCT116 WT or 
SLC25A46 knockout (SLC25A46−/−) cells was determined. Mitochondria from each cell line were 
isolated, solubilized, separated by SDS–PAGE, and analyzed with immunoblotting. Three different 
single-cell knockout clones designated 1.7, 4.1, and 4.3, using two different gRNAs. The asterisk 
marks a nonspecific band of the antibody. (C) Steady-state levels of MFN1 and MFN2 in HEK293 
T-REx Flp-In WT, and SLC25A46-/- cells were measured in three independent experiments. 
Mitochondria from each cell line were isolated, solubilized, separated by SDS–PAGE, and analyzed 
with immunoblotting. TOMM40 was included as a loading control. (D) Densitometric analysis of C. 
Results are shown as mean ± SEM of three independent experiments. t test, p < 0.05. (E) Analysis 
of MFN1 and MFN2 expression in HEK293 T-REx Flp-In WT and SLC25A46–/– cells by qPCR (mean 
± SEM, n = 3). (F) Knockout of SLC25A46 does not alter the phospholipid composition of 
mitochondria. Phospholipids were extracted from 0.75 mg of mitochondria in the cell lines as in B, 
separated by thin-layer chromatography, and visualized using molybdenum blue staining. Scanned 
images were analyzed using Quantity 1 software, and the relative abundance of each phospholipid 
was calculated as percentage of the total phospholipid in each sample (mean ± SEM, n = 3). CL, 
cardiolipin; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, 
phosphatidylinositol; PG, phosphatidylglycerol; PS, phosphatidylserine. 
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∼25% hyperfused mitochondria. Thus the 
mitochondrial network in LAN5 cells that 
lack SLC25A46 is aberrant, marked with a 
hyperfused network.
MFN1 and MFN2 oligomerization can 
be confirmed by cross-linking with a cyste-
ine–cysteine cross-linker, which yields high–
molecular weight complexes in SDS gels. In 
SLC25A46−/− HCT116 or LAN5 SLC25A46 
knockdown cells, an increased abundance 
of MFN1 and MFN2 oligomers was de-
tected by cross-linking (Supplemental 
Figure S5, A and B). Our results support the 
observation that decreased SLC25A46 ex-
pression leads to hyperfused mitochondria 
(Figure 3, D and E; Abrams et al., 2015; 
Wan et al., 2016), which correlates with 
increased steady-state levels and oligomer-
ization of MFN1 and MFN2 complexes in 
hyperfused mitochondria.
Because hyperfused mitochondria might 
influence cell viability, we analyzed the cell 
growth of HEK293 T-REx Flp-In SLC25A46−/− 
and LAN5 cells in which SLC25A46 expres-
sion was silenced by a specific shRNA 
(Figure 3F). However, changes in cell viabil-
ity were not detected in these lines (Figure 
3F). Our results contrast with a recent study 
by Janer et al. (2016) in which fibroblast 
lines derived from a patient or knocked 
down for SLC25A46 showed increased cell 
senescence.
Expression of SLC25A46 L341P does 
not rescue elevated MFN1 and MFN2 
levels in cells lacking SLC25A46
Next we analyzed whether mutant 
SLC25A46 L341P is able to rescue the phe-
notype in SLC25A46 knockout cells be-
cause our previous studies indicated that 
the L341P mutation destabilized SLC25A46, 
causing hyperfused mitochondria and 
lethal PCH (Wan et al., 2016). SLC25A46 
was deleted in HEK 293 T-REx Flp-In cells, 
and doxycycline-inducible 2xHA-SLC25A46 
WT or L341P was introduced. Isolated mi-
tochondria from these cell lines were 
FIGURE 3: SLC25A46 levels affect the steady-state levels and assembly of MFN1 and MFN2. 
(A) The oligomerization of MFN1 and MFN2 was determined in isolated mitochondria from 
LAN5 cell lines in which SLC25A46 was knocked down with different shRNA constructs after 
doxycycline induction using BN-PAGE and immunoblotting. (B) The steady-state levels of the 
indicated proteins were determined using the same mitochondrial extracts loaded on BN-PAGE 
in A. (C) Analysis of MFN1 and MFN2 expression in LAN5 cells in which SLC25A46 was knocked 
down with a specific shRNA construct by qPCR (mean ± SEM, n = 3). (D) The mitochondrial 
network in LAN5 cell lines in which SLC25A46 was knocked down after doxycycline induction 
was investigated by immunofluorescence staining using an antibody against the matrix protein 
Mortalin or OM protein TOMM20. 4′,6-Diamidino-2-phenylindole was used to stain the nucleus. 
Scale bar, 10 μm. (E) Quantification of the mitochondrial network from D. For each experiment, 
100 cells were counted (mean ± SEM, n = 3). (F) Live cells were quantitated using a trypan blue 
assay in the LAN5 and HEK294 T-REx Flp-In lines. An equal number of cells from each line was 
plated, and then live cells were counted after 4 d. The expression of SLC25A46 in LAN5 was 
knocked down for 2 wk before the experiment. Data represent mean ± SEM. (n = 3). (G) As in A, 
but the oligomerization of MFN1 and MFN2 was analyzed in HEK293 T-REx Flp-In cells lacking 
SLC25A46. SLC25A46 knockout was rescued 
by expressing 2xHA-SLC25A46 WT or L341P 
for 48 h after induction with 10 ng/ml 
doxycycline. (H) Lysates from G were 
separated by SDS–PAGE and the steady-
state levels of indicated proteins investigated 
by immunoblot. 2xHA-SLC25A46 and 
endogenous SLC25A46 were detected with 
anti-SLC25A46; a longer exposure to detect 
HA-SLC25A46 L341P of the panel was 
included. A panel with anti-HA was also 
included to detect expressed HA-SLC25A46 
WT and L341P.
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limited proteolysis. Membrane insertion was confirmed by alkali 
extraction (Figure 4E). In the absence of trypsin treatment, all 
three proteins were imported to the same extent. Comparison of 
the cleavage products after limited proteolysis showed that the 
three proteins had differing cleavage patterns. Three prominent 
degradation products were detected and labeled on the panel 
with the longer exposure. SLC25A46 WT and R340C had a promi-
nent cleavage product at position 2 and minor product at position 
1, with the exception that R340C had less of these products than 
WT. In contrast, SLC25A46 L341P had an additional cleavage 
product at position 3 that was more prominent than for WT and 
R340C. Thus we conclude that SLC25A46 L341P is imported 
subjected to SDS- and BN-PAGE as in Figure 3, A and B. Again, 
MFN1 and MFN2 showed increased steady-state levels and oligo-
merization when SLC25A46 was knocked out (Figure 3, G and H). 
Whereas the induction of 2xHA-SLC25A46 WT rescued the knock-
out, the induction of 2xHA-SLC25A46 L341P failed and instead in-
creased steady-state levels, and oligomerization of MFN1 and 
MFN2 prevailed (Figure 3, G and H). Note that expression of the 
HA-SLC25A46 proteins was confirmed by immunoblotting with an 
anti-HA antibody. In addition, anti-SLC25A46 was used to detect 
expression of endogenous SLC25A46 and HA-tagged SLC25A46; 
because 2xHA-SLC25A46 L341P is rapidly degraded, this panel was 
overexposed to verify that 2xHA-SLC25A46 L341P was present 
(Figure 3H). Thus cells expressing SLC25A46 L341P have a pheno-
type identical to that of SLC25A46 knockout.
SLC25A46 L341P is not stable
Because rapid turnover of a specific mitochondrial OM protein is an 
unexpected molecular basis for a disease, we investigated this deg-
radation pathway in detail. We transiently transfected HEK293T cell 
lines with constructs that expressed SLC25A46 WT or L341P mutant 
protein containing a 2xHA epitope at the N-terminus. We treated 
cells with cycloheximide to block cytosolic translation and removed 
aliquots in a time-course chase (Figure 4A). SLC25A46 was detected 
with an anti-HA antibody. Mitochondrial OM protein TOMM40 was 
included as a control. The abundance of SLC25A46 was quantitated 
by densitometry (Figure 4B). Whereas TOMM40 and WT SLC25A46 
were stable during the chase, SLC25A46 L341P was not detected, 
except when the blot was overexposed relative to WT SLC25A46. 
Note that the apparent increase in abundance of SLC25A46 at the 
40- and 60-min time points is unexpected but likely indicative of the 
normal variability associated with the stable protein in these types of 
experiments; we observed this previously (Hwang et al., 2007). To 
determine whether different amino acid substitutions were toler-
ated, changes including a basic (arginine, R), acidic (glutamate, E), 
and conservative hydrophobic (valine, V) substitution were made to 
SLC25A46 at position 341, and the stability was tested as in Figure 
4A (Figure 4C). Again, the arginine and glutamate substitutions 
markedly reduced stability, similar to the proline mutation, and the 
conservative valine substitution also decreased the stability of 
SLC25A46, but the protein was detectable upon a shorter exposure 
of the film. Therefore the mutation at position 341 strongly de-
creases the stability of SLC25A46.
Mutations in SLC25A46 were also identified in patients with op-
tic atrophy spectrum disorder (Abrams et al., 2015). These muta-
tions were associated with defects in mitochondrial morphology but 
the fate of mutant SLC25A46 protein was not determined. Two mu-
tations, P333L and R340C, were near L341P and localized to the 
putative fifth membrane-spanning domain, based on homology 
with mitochondrial carriers (Wan et al., 2016). As in Figure 4C, the 
abundance of these proteins was determined using cycloheximide-
chase studies (Figure 4D). SLC25A46 R340C was detected, but 
L341P and P333L variants were identified only when the blot was 
exposed for a longer time. The patient with the P333L mutant died 
at 15 wk of life, whereas the patient with the R340C mutation was 51 
yr old at the time of the study (Abrams et al., 2015). Thus rapid turn-
over of SLC25A46 during development is likely associated with the 
early onset of death.
To determine whether the rapid degradation of SLC24A46 
L341P was a result of the mutant protein failing to reach its native 
conformation in the OM after import, we imported radiolabeled 
SLC25A46 WT, L341P, and R340C into isolated mitochondria and 
treated half of the sample with a low amount of trypsin to perform 
FIGURE 4:  SLC25A46 L341P is very unstable in cultured cells and 
does not reach its native conformation. (A) The half-life of WT 
SLC25A46 or SLC25A46 L341P was determined by cycloheximide 
(CHX)-chase experiments. HEK293T cells were transiently transfected 
with constructs for 2xHA-SLC25A46 WT or 2xHA-SLC25A46 L341P. 
At 24 h posttransfection, CHX was added, and samples were taken 
at the indicated time points. The mitochondria were isolated and 
analyzed with antibodies against the HA tag and control TOMM40. 
(B) Densitometry of immunoblots from A. (C) As in A, constructs were 
generated with the indicated mutations at position 341. (D) As in A, 
constructs were generated with the indicated mutations at positions 
341, 333, and 340. (E) Radiolabeled 2xHA-SLC25A46 WT, L341P, and 
R340C were imported for 10 min into mitochondria isolated from 
HEK293 T-REx Flp-In cells. After import, half of the sample was 
treated with 1.25 μg/ml trypsin for 15 min on ice, and inserted 
proteins were recovered in the pellet after alkali extraction. As a 
control, the other half was incubated for 15 min on ice, followed by 
alkali extraction. All samples were resolved by SDS–PAGE and 
visualized by autoradiography. Arrows labeled 1–3 indicate different 
cleavage products that were prominent in the panel that was exposed 
for a longer time.
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SLC25A46 L341P is polyubiquitylated 
and degraded by the proteasome
The strong interaction of SLC25A46 L341P 
with MULAN implies that mutant SLC25A46 
may be rapidly degraded by the UPS 
(Figure 2A). However, it has been sug-
gested that mitochondrial OM proteins are 
turned over only by mitophagy with the 
ultimate removal of the entire organelle 
(Ling and Jarvis, 2013). Therefore we in-
vestigated the turnover process in more 
detail. Cells expressing SLC25A46 L341P 
were treated with the two proteasome in-
hibitors MG132 and bortezomib and with 
the late-phase autophagy inhibitor bafilo-
mycin A1 (Figure 5A). Because MG132 at a 
10-fold higher concentration can also in-
hibit the proteolytic calpains and cathes-
pins (Tsubuki et al., 1996; Kisselev and 
Goldberg, 2001), bortezomib, which is pro-
teasome specific, was also used (Moore 
et al., 2008). The steady-state level of 
SLC25A46 L341P was increased only when 
the cells were treated with MG132 or bort-
ezomib (Figure 5A). Proteins that are de-
graded by the proteasome are typically 
ubiquitylated, resulting in a decreased mo-
bility in SDS gels. A fraction of SLC25A46 
L341P displayed reduced mobility after 
proteasome inhibition, suggesting ubiqui-
tylation (Figure 5A; the monoubiquitylated 
fraction is marked with an asterisk). In con-
trast, SLC25A46 L341P was not stabilized 
upon bafilomycin A1 treatment, although 
the autophagy marker LC3-II accumulated, 
indicating autophagy was indeed inhibited 
(Figure 5A). When we analyzed mitochon-
dria from HEK293T cells that were tran-
siently transfected with HA-SLC25A46 WT 
or L341P mutant, we found that MG132 
treatment again markedly stabilized HA-
SLC25A46 L341P, whereas HA-SLC25A46 
WT was only slightly stabilized (Figure 5B). 
Moreover, a fraction of the SLC25A46 WT 
and L341P from MG132-treated cells also 
showed decreased mobility after increased 
exposure, supporting ubiquitylation of 
the proteins (Figure 5B). In HeLa cells 
transiently transfected with HA-tagged 
SLC25A46 WT or L341P, mutant SLC25A46 
was barely detectable (Supplemental 
Figure S6) and localized to mitochondria 
and the cytosol; however, no large aggre-
gates were observed. In comparison, 
SLC25A46 WT was abundant and exclu-
sively localized to mitochondria. When the 
cells were treated with MG132, SLC25A46 L341P and WT accumu-
lated on mitochondria and in the cytosol. We conclude that 
SLC25A46 L341P does not form large aggregates but is imported 
into mitochondria and then is quickly retrotranslocated to the 
cytosol due to instability. WT SLC25A46 follows a similar pathway 
but with slower kinetics.
normally but does not reach the native conformation, resulting 
in rapid degradation. That SLC25A46 L341P does not fold into 
its final conformation is also supported by the observation that 
SLC25A46 L341P displayed a different distribution pattern in 
the glycerol gradients and BN-PAGE than did WT SLC25A46 
(Figure 1, A and C).
FIGURE 5: SLC25A46 L341P is polyubiquitylated and degraded by the proteasome. (A) HEK293 
T-REx Flp-In cells expressing 2xHA-SLC25A46 L341P were treated with MG132, bortezomib, 
bafilomycin A1, or DMSO (0.1%) for 6 h. Cells were lysed, and total extracts were analyzed by 
SDS–PAGE. Antibodies against LC3 and ubiquitin were included as controls to verify inhibition 
of autophagy and protein degradation, respectively. TOMM40 served as loading control. The 
asterisk marks monoubiquitylated 2xHA-SLC25A46 L341P. (B) SLC25A46 L341P accumulates on 
mitochondria upon proteasome inhibition. HEK293T cells were transfected as in A and then 
treated with 10 μM MG132 (M) or control DMSO (D) for 6 h. Mitochondria were isolated and 
lysed; HA-tagged SLC25A46 L341P was detected by immunoblotting. (C) Ubiquitylated 
SLC25A46 WT or L341P was immunoprecipitated under denaturing conditions with a Flag 
antibody from cells transiently expressing HA-ubiquitin-GFP and 3xFlag-SLC25A46 WT or 
L341P. Ubiquitin was detected with an anti-HA antibody. GFP cleaved from HA-ubiquitin 
served as transfection control, and TOMM40 was included as a loading control. (D) The ratio 
between ubiquitylated and nonubiquitylated SLC25A46 WT and L341P was determined after 
densitometric analysis of both proteins pools of C. Mean ± SEM n = 3. (E) Proteasome inhibition 
blocks the rapid degradation of SLC25A46 L341P in mitochondria. HEK293T were transiently 
transfected with constructs for 2xHA-SLC25A46 WT or L341P for 24 h and then harvested 
before (0) and 15 or 30 min after the addition of cycloheximide. Mitochondria were isolated 
and analyzed by SDS–PAGE and immunoblotting. To block proteasome-dependent degradation, 
25 μM MG132 was added at the time as cycloheximide addition.
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expected, SLC25A46 was ubiquitylated, 
with the mutant L341P possessing greater 
modification (Figure 5, C and D).
To verify the UPS involvement in the 
turnover of SLC25A46, were subjected cells 
transiently transfected with SLC25A46 WT 
or L341P to a cycloheximide chase in the 
presence of the MG132 to assess SLC25A46 
stability (Figure 5E). SLC25A46 WT was sta-
ble, whereas SLC25A46 L341P was present 
at lower levels, but degradation was de-
tected upon longer exposure to film. The 
addition of MG132 stabilized the SLC25A46 
L341P, confirming that the proteasome de-
graded mutant L341P. TOMM40 was stable 
and included as a loading control. Thus 
SCL25A46 L341P in the mitochondrial OM 
is extensively ubiquitylated and degraded 
by the proteasome, independently of 
mitophagy.
MULAN and MARCH5 coordinately 
ubiquitylate SLC25A46 L341P, and P97 
mediates the degradation of SLC25A46
We determined the components that medi-
ate SLC25A46 turnover by taking advan-
tage of inhibitors, mutants, and RNAi silenc-
ing. When HEK293T cells stably expressing 
SLC25A46 L341P were treated with the pro-
teasome inhibitor MG132 (M) or P97 inhibi-
tor NMS873 (N; Magnaghi et al., 2013), 
coIP assays revealed a robust interaction of 
SCL25A46 L341P with MULAN and a 
weaker interaction with P97 (Figure 6A). A 
strong interaction with MARCH5 was not 
detected, because MARCH5 failed to coim-
munoprecipitate with SCL25A46 L341P 
(Figure 6A). Note that immunoblots with 
the antibody for endogenous MARCH5 
yield some background, and a nonspecific 
band that migrates at a higher molecular 
weight than MARCH5 was detected 
(marked with an asterisk in Figure 6A).
We followed this investigation with 
cycloheximide-chase experiments to stop 
cytosolic translation and investigated 
SLC25A46 L341P stability under condi-
tions that decreased proteolysis (Figure 6, 
B–D). Aliquots were removed before cyclo-
heximide treatment and 15 and 30 min 
posttreatment, and mitochondria lysates 
were subjected to immunoblotting. Treat-
ment with NMS873 to inhibit P97 before 
the cycloheximide chase resulted in 
SLC25A46 L341P accumulating in large–
molecular mass complexes (marked with 
an asterisk), indicating an accumulation of 
polyubiquitylated SLC25A46 L341P mutant on mitochondria 
(Figure 6B). We do not expect that this fraction of SLC25A46 
(marked with an asterisk) is a nonspecific aggregate because 1) the 
high–molecular mass form of SLC25A46 was not detected when 
the cells were mock treated with dimethyl sulfoxide (DMSO); 2) the 
To confirm SLC25A46 ubiquitylation, we transiently transfected 
cells with Flag-tagged SLC25A46 WT or L341P, as well as with a 
construct for HA-tagged ubiquitin-GFP (and as a control, an empty 
vector; Figure 5C). SLC25A46 from lysates was immunoprecipitated 
with anti-Flag followed by immunoblotting with anti-HA. As 
FIGURE 6: Rapid turnover of SLC25A46 L341P strongly depends on P97. (A) SLC25A46 binds 
to P97, MARCH5, and MULAN. Stable HEK293T cells expressing 2xHA-SLC25A46 L341P were 
treated with DMSO (vehicle control), 25 μM MG132 (M), or 5 μM NMS873 (N) for 3 h before cell 
lysis. Cells were lysed in digitonin, and SLC25A46 was immunoprecipitated from whole-cell 
extracts with anti-HA antibody. Antibodies against HA, P97, MULAN, and matrix control LRP130 
were used for immunoblotting. Input samples correspond to 2% of the amount of lysate used 
for the IP. The asterisk marks an unspecific signal in the IP lanes for MARCH5. (B) Inhibition of 
P97 alters degradation of SLC25A46 L341P. The same cells as in A were treated with DMSO and 
5 or 10 μM NMS873 in combination with CHX. At the indicated times, cells were harvested and 
mitochondria were isolated. SLC25A46 L341P degradation was detected by immunoblotting, 
and TOMM40 was included as a loading control. The asterisk marks polyubiquitylated species. 
(C) HEK293T cells stably expressing doxycycline (Doxy)-inducible shRNA targeting P97 were 
transfected with a construct for 2xHA-SLC25A46 L341P. After 24 h, cells were treated with CHX, 
and samples were removed at the indicated times. Cells were separated into a mitochondrial 
pellet and a postmitochondrial supernatant; equal amounts of protein from each fraction were 
analyzed by SDS–PAGE and immunoblotting. Doxycycline treatment was started 24 h before 
transfection and maintained during the analysis. The asterisk marks monoubiquitylated 
SLC25A46. (D) The half-life of SLC25A46 L341P was determined in HEK293T cells transiently 
expressing 2xHA-SLC25A46 L341P in combination with WT P97, active-site-mutant P97-QQ, or 
empty vector. Cells were treated with CHX and analyzed as described in C. The asterisk marks 
monoubiquitylated SLC25A46.
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samples were prepared for SDS–PAGE 
with a sample buffer that contained SDS, 
resulting in the expected solubilization of 
SLC25A46; and 3) SLC25A46 prepared in 
SDS-containing sample buffer is not ob-
served in the stacking gel, and the 
SLC25A46 fraction at the top of the gel 
(marked with an asterisk) entered into the 
separating gel. P97 protein expression was 
decreased using a doxycycline-inducible 
shRNA system (Figure 6C). Decrease in 
P97 protein levels correlated with in-
creased stability of SLC25A46 L341P on 
mitochondria and a slight increase in the 
stability of a cytosolic pool. This supports a 
pathway in which SLC25A46 is first in-
serted into the mitochondrial OM and then 
subsequently degraded. In addition, ex-
pression of the active-site P97-QQ mutant 
mirrored the shRNA induction (Figure 6D), 
in which SLC25A46 L341P was stabilized 
on the mitochondrial membrane; more-
over, a monoubiquitylated form of 
SLC25A46 L341P (marked with an asterisk) 
was detected, and a fraction of the P97-
QQ mutant associated with the SLC25A46 
mutant on mitochondria. In contrast, over-
expression of active P97 did not increase 
accumulation of mutant SLC25A46 (Figure 
6D). Note that in Figure 6C with anti-P97, a 
fraction of the P97 pool was detected in 
the mitochondrial fraction, which likely re-
flects a pool of P97 that might be engaged 
in SLC25A46 degradation. Similarly, a 
small fraction of the P97-QQ mutant was 
identified in the mitochondrial fraction; this 
pool may be larger because the anti-histi-
dine antibody is not as robust as the P97 
antibody.
We manipulated MULAN expression. 
Overexpressing MULAN resulted in in-
creased monoubiquitylation of SLC25A46 
L341P (marked with an asterisk). However, 
“ligase-dead” MULAN H319A increased 
SLC25A46 L341P stability but lacked ubiqui-
tylation (Zhang et al., 2008; Figure 7A). 
FIGURE 7: MARCH5 and MULAN mediate SLC25A46 L341P ubiquitylation and degradation. 
(A) Increased half-life of SLC25A46 L341P by overexpressing the RING-finger mutant MULAN 
H319A. A stable cell line expressing 2xHA-SLC25A46 L341P was transiently transfected with an 
empty vector, WT MULAN, or MULAN H319A and treated with CHX for indicated time points. 
Mitochondria were isolated, and MULAN was detected with an anti-myc antibody. The asterisk 
marks monoubiquitylated SLC25A46. (B) As in A, with the exception that the cells were 
transiently transfected with WT MARCH5 or the RING-mutant MARCH5 H43W. (C) HEK293T 
cells stably expressing Doxy-inducible control shRNA or a shRNA targeting MULAN were 
transfected with constructs for control shRNA or shRNA targeting MARCH5 and 2xHA-
SLC25A46 L341P. Doxycycline (1 μg/ml) was added during transfection. After 48 h, CHX was 
added, and cells were harvested just before CHX addition (0) and at 15 and 30 min. 
Mitochondria were isolated and analyzed by SDS–PAGE and immunoblotting. (D) As in C, but 
cells were transfected with 3xFlag-SLC25A46 L341P and HA-Ubiquitin-GFP. After treatment of 
the cells with 25 μM MG132 for 3 h, HA-tagged ubiquitylated proteins were immunoprecipitated 
under denaturing conditions with anti-HA. Ubiquitylated 3xFlag-SLC25A46 L341P was detected 
with an anti-Flag antibody. The asterisk marks polyubiquitylated species. TOMM40 is a loading 
control. (E) Determination of SLC25A46 L341P abundance in HEK293 T-REx Flp-In WT, MARCH5, 
MULAN, or MARCH5/MULAN knockout cells. Cells were transfected with a 2xHA-SLC25A46 
L341P construct; mitochondria from the cell lines were isolated, solubilized, separated by 
SDS–PAGE, and analyzed by immunoblotting. PreP was included as a loading control. (F) As in E, 
with CHX treatment for the indicated times. Cells were harvested at each time point, and 
mitochondria were isolated. SLC25A46 L341P and endogenous SLC25A46 were detected by 
immunoblotting, and TOMM40 was included 
as a loading control. (G) Under physiological 
expression of WT SLC25A46, the levels of 
MFN1, MNF2, and dimers are kept constant 
so as not to disturb the fine balance between 
fission and fusion, which is important for 
development and survival (left). However, 
when the gene SLC25A46 is disrupted by 
deletions or the gene product destabilized 
by point mutations like L341P, which is 
quickly degraded by OM–associated 
degradation, MFN1 and MFN2 dimers 
accumulate on the OM and shift the balance 
towards fusion. This leads to pontocerebellar 
hypoplasia and early death (right).
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CRL3 substrate (Emanuele et al., 2011). The small molecule 
MLN4924, which inhibits the NEDD8-activating enzyme and thereby 
prevents the activation of Cullin RING ligases, was added to cells 
before the cycloheximide chase (Soucy et al., 2009). SLC25A46 
L341P was not stabilized under these conditions. However, the in-
hibitor was active because it prevented the neddylation of Cul4a by 
Nedd8 (Brownell et al., 2010). Thus, of the ubiquitin ligases, 
MARCH5 and MULAN coordinate SLC25A46 degradation and 
seem to have redundant functions.
DISCUSSION
SLC25A46 is a regulator of mitochondrial dynamics and morphology. 
SLC25A46 interacts with fusion regulators MFN1, MFN2, and OPA1. 
In cells with decreased SLC25A46, the abundance of MFN1and 
MFN2 was elevated, and the pool shifted to that of an assembled 
oligomeric complex; this correlates with knockdown of SLC25A46 
resulting in hyperfused mitochondria (Figure 3E; Abrams et al., 2015; 
Wan et al., 2016). Whereas SLC25A46 associated with the MICOS 
complex, SLC25A46 knockout did not change the abundance of 
MICOS components; this seemed to have little effect on cristae mor-
phology (Abrams et al., 2015; Wan et al., 2016). Abrams and col-
leagues describe SLC25A46 as a Ugo1-like, OM carrier–like protein 
that interacts with the yeast MFN1/MFN2 counterpart, Fzo1, and 
with the MICOS complex component Fcj1 (Sesaki and Jensen, 2004; 
Harner et al., 2011; Abrams et al., 2015). However, deletion of Ugo1 
results in mitochondrial fusion defects, reduced levels and oligomer-
ization of Fzo1, and altered cristae morphology (Sesaki and Jensen, 
2004; Harner et al., 2011); this is the opposite of the SLC25A46 
knockout phenotype that we describe here. Ugo1 is also suggested 
to regulate the local lipid composition in the OM, thereby facilitating 
mitochondrial fusion (Hoppins et al., 2009). However, we did not de-
tect differences in the mitochondrial phospholipid profile in cells 
lacking SLC25A46. Furthermore, Ugo1 seems to be important for 
linking Fzo1 with the IM MICOS subunit Fcj1 and regulating IM and 
OM fusion (Sesaki and Jensen, 2004; Harner et al., 2011). A recent 
study suggests that SLC25A46 also functions with the MICOS com-
plex, mediates lipid trafficking, and regulates mitochondrial respira-
tion (Janer et al., 2016). However, we did not report the same 
phenotype.
A potential reason for the different phenotypes might be the 
cell type studied, which emphasizes that mitochondrial dynamics 
pathways function differently in different cell types. Janer et al. 
(2016) primarily studied phenotypes in patient fibroblasts, in con-
trast to our studies in a variety of transformed cell types, including 
neuronal cells. We conclude that a subset of functions between 
SLC25A46 and Ugo1 may be conserved, whereas other functions 
developed differently; this is also likely a reflection of the in-
creased complexity of multicellular organisms versus yeast. 
SLC25A46 interacts with a large number of proteins involved in 
mitochondrial ultrastructure, likely in transient complexes that 
were stabilized by cross-linking. Similar results were described for 
Ugo1 because Ugo1 interactions with Fzo1 and Mgm1 were also 
detected only after cross-linking (Wong et al., 2003). Therefore 
SLC25A46 might function as a coordination point to facilitate 
rapid changes in mitochondrial ultrastructure in response to 
changes in the microenvironment by regulating the stability, as-
sembly, and disassembly of proteins important for mitochondrial 
dynamics and cristae morphology.
Regulating the levels of SLC25A46 also seems to be important 
for its function. Our analysis shows that both MARCH5 and MU-
LAN are ubiquitin ligases that contribute to the selective and rapid 
degradation of SLC25A46 L341P. Moreover, the ubiquitylated 
Initially, we anticipated that overexpression of WT MULAN would 
result in increased turnover of SLC25A46 L341P, similar to the condi-
tions of the empty vector control. However, overexpression of MU-
LAN is likely not well tolerated by cells because reports indicate that 
overexpression of WT MULAN inhibits cell growth and causes cell 
death (Zhang et al., 2008; Bae et al., 2012). Therefore we interpret 
this result as indicating that increased abundance of active MULAN 
causes increased degradation of key proteins required for cell sur-
vival, such as Akt (Bae et al., 2012), and long-term MULAN overex-
pression leads to apoptosis via activation of caspases (Zhang et al., 
2008). Indeed, long-term overexpression of MULAN leads to cell 
death in these experiments. We conclude that under apoptotic con-
ditions, the quality control pathway for proteins such as SLC25A46 
L341P is not working efficiently and therefore SLC25A46 turnover is 
not as robust as in the case of expression of the empty vector. In ad-
dition, a similar result was found with the endoplasmic reticulum (ER) 
ubiquitin ligase HRD1. Overexpression of the mutant HRD1 failed to 
degrade nonsecreted immunoglobulin κ light chain (Ig κ LC), but 
overexpression of WT HRD1 also inhibited degradation of nonse-
creted Ig κ LC (Okuda-Shimizu and Hendershot, 2007). Thus the 
results with HRD1 mirror those with overexpression of WT MULAN.
We used a similar approach with manipulation of MARCH5 ex-
pression. Transient transfection of WT MARCH5 resulted in degra-
dation of SLC25A46 L341P similar to the transfection with an empty 
vector (Figure 7B). In contrast, transfection with the ring-domain 
mutant MARCH5 H43W resulted in stabilization of SLC25A46 L341P 
to a minor extent (Karbowski et al., 2007).
Using the shRNA approach to decrease MULAN and MARCH5 
expression, we found that SLC25A46 L341P was markedly stabilized 
when the expression of both was reduced (Figure 7C). To confirm 
ubiquitylation of SLC25A46 L341P specifically by MULAN and 
MARCH5, we combined Flag-tagged SLC25A46 L341P and HA-
ubiquitin–green fluorescent protein (GFP) transfection with the 
MULAN and MARCH5 RNAi treatment as in Figure 5C. Again, 
knockdown of both MULAN and MARCH5 shifted the pool of polyu-
biquitylated SLC25A46 L341P to a cohort that was less ubiquity-
lated (Figure 7D, asterisk). As in Figure 6B, we do not expect the 
fraction of Flag-SLC25A46 L341P that migrates at a high molecular 
mass (asterisk) to be a nonspecific aggregate because this fraction 
was not detected in the sample treated with the control shRNA. In 
addition, on the basis of the assay, we first immunoprecipitated 
proteins that were HA-ubiquitylated and then blotted for Flag-
SLC25A46 L341P with anti-Flag. Therefore the fraction of Flag-
SLC25A46 L341P that migrates at a high molecular mass (asterisk) is 
polyubiquitylated.
To verify the role of MULAN and MARCH5 on the degradation of 
SLC25A46 L341P, we generated HEK293 T-REx Flp-In MULAN−/−, 
MARCH5−/−, and MULAN−/−/MARCH5−/− cell lines and analyzed the 
abundance of the SLC25A46 L341P when transiently transfected 
(Figure 7E). Again, only in the absence of MARCH5 and MULAN 
were SLC25A46 L341P steady-state levels increased in comparison 
to the single E3 ligase knockouts. As observed in the shRNA ap-
proach, SLC25A46 L341P was stabilized markedly when both E3 li-
gases were knocked out in the HEK293 T-REx Flp-In cell lines (Figure 
7F). Single knockout of MULAN or MARCH5 had little effect on the 
half-life of SLC25A46.
The Cullin RING ligase family does not ubiquitylate 
SLC25A46 L341P
Another class of E3 ubiquitin ligases that may play a role in degrad-
ing SLC25A46 L341P is the Cullin RING ligase (CRL) family (Supple-
mental Figure S7). Previously SLC25A46 was identified as a potential 
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development and maturation of cerebellar Purkinje neurons (Chen 
et al., 2007).
MATERIALS AND METHODS
Cell culture and transfection
HeLa (American Type Culture Collection [ATCC]), HEK293 T-REx Flp-
In (Life Technologies), HEK293T (ATCC), LAN5 (provided by Joan 
Valentine, University of California, Los Angeles [UCLA], Los Angeles, 
CA), and HCT116 (provided by Richard Youle, National Institutes of 
Health, Bethesda, MD) were cultured in DMEM (high glucose, so-
dium pyruvate), RPMI (Life Technologies), and McCoy’s 5A (GE 
Healthcare) media, respectively, and grown at 37°C in 5% CO2. 
Media were supplemented with 10% fetal bovine serum (Atlanta 
Biological), 100 U/ml penicillin, and 100 μg/ml streptomycin (Life 
Technologies). Transfections were performed using BioT transfec-
tion reagent (Bioland) or Lipofectamine 2000 (Thermo Fisher Scien-
tific) according to the manufacturer’s instructions.
Chemicals and antibodies
MG132 (Enzo Biochem), NMS873 (Selleck Chemicals), bortezomib, 
bafilomycin A1, and MLN4924 (EMD Millipore) were dissolved in 
DMSO, stored at −80°C, and used at the indicated concentrations. 
DMSO at 0.1% served as the vehicle control.
Antibodies used in this study were SLC25A46 (Proteintech); HA 
(HA.11; Biolegend); MFN1 (ab57602) and histidine (HIS.H8; Ab-
cam); LC3A/B (Cell Signaling); MFN2 (D1E9; Cell Signaling); MTCH2 
(Abgent); MIC60/IMMT (Abgent and Proteintech); MID51 (Protein-
tech); Ubiquitin (FK2, Enzo Biochem); Mortalin (University of Califor-
nia, Davis/National Institutes of Health NeuroMab Facility); MIC19/
CHCHD3 (Everest Biotech); MIC27/Apool (Assay BioTech); OPA1, 
P97/VCP, and TIMM23 (BD Biosciences); TOMM20 (FL-145), LRP130 
(H-300), and glyceraldehyde-3-phosphate dehydrogenase (FL-335; 
Santa Cruz Biotechnology); MULAN (HPA017681) and Flag (M2) 
(Sigma-Aldrich); MARCH5 (provided by Richard Youle); myc (9E10; 
Developmental Studies Hybridoma Bank, University of Iowa); and 
Cullin 4a (PA5-29857; Thermo Fisher Scientific). PREP, GFP, 
TOMM40, YME1L, and PNPase polyclonal antibodies were raised 
against recombinant proteins (Pacific Immunology).
Genome editing by CRISPR/Cas9
We transfected 106 HCT116 or HEK293 T-REx Flp-In cells in a six-well 
plate with constructs coding for SLC25A46, MUL1, and MARCH5 
guide RNAs (gRNAs) and Cas9 endonuclease using BioT (Bioland) 
according to manufacturer’s protocol. After 24 h, the cells were split 
into 6-cm dishes and selected with 2 μg/ml puromycin for 2 d. Puro-
mycin was removed, and cells were grown in puromycin-free medium 
to confluency. Single-cell colonies were obtained by plating at 0.5 
cell per 96 well. Colonies were expanded and analyzed by a T7 endo-
nuclease cleavage assay, DNA sequencing, and immunoblotting.
Pulse-chase assays with cycloheximide
Cells were treated with 50 μg/ml cycloheximide (Sigma-Aldrich) for 
0, 15, and 30 min. Where indicated, additional inhibitors were 
added at the same time as cycloheximide (MG132 or NMS873) or 
1 h before the addition of cycloheximide (MLN4924). At each time 
point, cells were washed once with homogenization buffer (20 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, 220 mM 
mannitol, 70 mM sucrose, 0.5 mM phenylmethylsulfonyl fluoride, 
2.5 mM NaF, 1 mM Na3VO4, 10 mM N-ethylmaleimide, and 10 μM 
MG132), scraped in homogenization buffer using a Teflon cell lifter, 
transferred to 1.5-ml tube, and flash frozen in liquid nitrogen. Frozen 
pellets were stored at −80°C until mitochondria were isolated.
SLC25A46 is subsequently removed from the mitochondrial OM 
via P97 and degraded by the proteasome, leading to an almost 
SLC25A46-null allele. The UPS has been described for the degra-
dation of certain native OM proteins such as MFN1, MFN2, and 
MCL1 under stress conditions such as apoptosis or mitophagy 
(Ling and Jarvis, 2013). However, very little is understood about 
the selective degradation of OM proteins that fail to reach their 
native conformation. Thus our study expands the role of the UPS 
in a protein quality control pathway for the removal of misfolded 
proteins from the mitochondrial OM.
We speculate that point mutations such as L341P or P333L locate 
to important regions of SLC25A46, and mutant SLC25A46 signals to 
the UPS for rapid removal. This is akin to the pathway for removal of 
mutant plasma membrane protein cystic fibrosis transmembrane 
conductance regulator (CFTR). Specifically, the single amino acid 
deletion of phenylalanine 508 in CFTR results in retention in the ER 
and subsequent degradation by the UPS (Younger et al., 2006; 
Morito et al., 2008). Based on our results, organelles have devel-
oped similar quality control pathways using organelle-specific ubiq-
uitin ligases and the cytosolic components of the UPS to deal with 
misfolded proteins. The mass spectrometry data (Supplemental 
Table S1) and coIP experiments (Figure 2A) indicated that the two 
E3 ubiquitin ligases MULAN and MARCH5 were primary candidates 
to initiate removal of SLC25A46 L341P. Cells with single knock-
downs of MULAN or MARCH5 showed partial stabilization of 
SLC25A46 L341P, whereas decreasing active MULAN and MARCH5 
together resulted in marked stabilization of SLC25A46 L341P with 
reduced ubiquitylation. Because the point mutation in SLC25A46 
likely resides in the membrane environment, MULAN and MARCH5, 
both integral OM proteins, are the likely players for monitoring as-
sembly of OM proteins (Campello et al., 2014). MARCH5 and MU-
LAN seem to have partially overlapping activities and coordinate 
ubiquitylation of SLC25A46.
SLC25A46’s role in the regulation of assembly and disassembly of 
proteins in dynamics and cristae morphology seems to be very im-
portant for neuronal development. Mutations L341P and P333L 
caused fast turnover of SLC25A46 and result in severe malformation 
of the cerebellum and motor neurons and finally early death. In con-
trast, mutations at R340C, E335D, and G249D resulted in a protein 
with greater stability, and patients had milder phenotypes (Abrams 
et al., 2015; Wan et al., 2016). Specifically, those patients developed 
to adulthood and suffered from neuronal diseases such as CMT type 
2A and DOA, which are also caused by mutations in mitochondrial 
dynamics proteins (Alexander et al., 2000; Züchner et al., 2004; 
Abrams et al., 2015). Thus it is of great interest that SLC25A46 carry-
ing those mutations was much more stable than SLC25A46 carrying 
mutation L341P or P333L (Wan et al., 2016). Therefore the effect of 
mutations in SLC25A46 on neuronal development highly correlates 
with how the mutation destabilizes the protein. Again, this was veri-
fied with another family, in which a homozygous deletion of 1897 
nucleotides within the SLC25A46 gene resulted in cerebellar malfor-
mation and early death as well (Wan et al., 2016). The deletion re-
sulted in loss of exon 1, which contained the start codon ATG for the 
longest and most prominent transcript and thus resulted in a gene 
knockout. These studies support an essential role of SLC25A46 in 
neuronal development. In sum, this analysis shows that the rapid 
degradation of SCL25A46 L341P likely causes pontocerebellar hy-
poplasia, a neuronal disease affecting mostly the cerebellum and 
motor neurons (Wan et al., 2016), by disrupting the fine balance be-
tween fission and fusion in the mitochondrial network. This is in 
agreement with the observation that defects in fusion-mediating 
MFN2, which is regulated by SLC25A46, drastically disrupt the 
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Biochemical assays
Standard protocols were used for mass spectrometry and biochemi-
cal experiments with mitochondria. For detailed protocols, see the 
Supplemental Materials and Methods.
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